Skip to content

A Clinical Study to Collect Calibration & Performance Data of the KBS Systems 1.0 Non-Invasive Glucose Monitoring Device

A Clinical Study to Collect Calibration & Performance Data of the KBS Systems 1.0 Non-Invasive Glucose Monitoring Device

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03607435
Enrollment
300
Registered
2018-07-31
Start date
2018-08-02
Completion date
2019-07-31
Last updated
2018-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Brief summary

The purpose of this study is to calibrate the performance of the KBS-1 non-invasive glucose monitoring device with diabetic people when compared to that of the standard method currently used in the clinical setting for prescription point-of-care (POC) blood glucose monitoring. The secondary purpose of this study is to calibrate the performance of the RBA-1 minimally invasive bodily fluid analyte analyzer device when compared to the results from a prescription POC blood glucose monitoring device and/or standard hospital laboratory blood test. The objective of this study is to collect non-invasive in vivo, and potentially in vitro, spectral measurements of interstitial fluid glucose from underneath the skin of the palm of the hand (Test Article #01), and potentially the blood, respectively, from diabetic adult hospital staff participants, and to collect in vitro spectral measurements of venous blood tested from adult hospital patients with or without diabetes (Test Article #02) and compare them to POC blood glucose monitor values and analyte measurements conducted by a hospital laboratory (Control Article #01 procedure), respectively. The comparison of the results obtained from the different analytical methods will be used to calibrate and refine the glucose, and other, analyte level calculation algorithms of the Test Article systems.

Interventions

DEVICESpectroscopy for Analyte Quantification

Diabetic hospital staff participants subjected to the KBS-1 device (Test Article #01) will have a finger on their left hand pricked with a lancet and their blood glucose level read by a POC glucose monitor (Control Article #02). Next, they will have their interstitial fluid glucose level spectroscopically scanned from the palm of their left hand using the KBS-1 device, and blood (approximately 40µl), collected from their finger prick site, will be spectroscopically scanned using the RBA-1 device (Test Article #02). Hospital patients subjected to the RBA-1 device, who must already be prescribed a hospital lab blood test by their physician, will have approximately 40µl of their blood, collected from the venipuncture site, spectroscopically scanned using the RBA-1 device (Test Article #02).

Sponsors

Kaligia Biosciences, LLC
CollaboratorINDUSTRY
Florida Hospital Tampa Bay Division
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Ideally, all enrolled participants will represent an ethnically diverse population with as close to an even ratio of males to females as possible. 1\) Age ≥ 21 years. 2) Willingness and ability to provide informed consent. * Additional inclusion criteria specific to KBS-1 (Test Article #01) testing: 1\) Diabetic hospital staff * Additional inclusion criteria specific to RBA-1 (Test Article #02) testing: 1. Hospital patients with a physician prescribed hospital laboratory blood test. 2. Diabetic hospital staff

Exclusion criteria

The following

Design outcomes

Primary

MeasureTime frameDescription
Calibration of the KBS-1 Test Article using the POC Control data for comparison.The test article and control article procedure together will take approximately 10 - 15 minutes of the research participant's time.The data gathered by the Test Article procedures will be compared to the data gathered by the POC Control Article procedure in order to accomplish: * Comparative analysis of the Test data against the Control data. * Test Article calibration and aid in Test Article machine learning. This is being requested to achieve calibration of the test articles, and aid in test article machine learning for glucose level calculations.

Secondary

MeasureTime frameDescription
Research Subject AssessmentThe assessment will take place immediately at the conclusion of the KBS-1 and POC glucose monitoring procedure and will take approximately 1 minute of the research participant's time.The research subjects will be questioned on the presence (Y or N) of any pain or discomfort related to the KBS-1 test article procedure, as well as ease of use and acceptability (1-5 rating scale, 1=bad, 5=excellent).
Calibration of the RBA-1 Test Article using the hospital lab test Control data and POC blood glucose monitor Control data for comparison.The test and control article procedure together will take approximately 10 minutes of a research participant's time.The data gathered by the Test Article procedure will be compared to the data gathered by the Control Article procedure(s) in order to accomplish: * Comparative analysis of the Test data against the Control data. * Test Article calibration and aid in Test Article machine learning. The analyte data from the hospital lab is being requested to achieve calibration of the test article, and aid in test article machine learning, for these analytes.

Countries

United States

Contacts

Primary ContactPatrick J Stocker, PhD
pstocker@kaligiabiosciences.com727-234-8874
Backup ContactFazal Fazlin, BS
ffazlin@kaligiabiosciences.com727-234-8877

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026